Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals demonstrated strong financial growth, ending the fourth quarter of 2025 with $2.67 billion in cash and equivalents, a noteworthy increase from $2.24 billion in the previous quarter. The company anticipates revenue growth to exceed operational expenditures, bolstered by successful product launches, including the recent 56% quarter-over-quarter revenue growth from its Tryngolza treatment for FCS, which indicates robust patient demand. Additionally, Ionis’s partnership launches, such as Wainua and the successful performance of olezarsen, contribute positively to its financial outlook, reinforcing the prospect of continued growth and market expansion through 2026.

Ionis Pharmaceuticals is facing a negative outlook primarily due to anticipated revenue declines and significant operating losses, with expected total revenue for 2026 projected between $800 million to $825 million, which falls short of the consensus estimate of $914 million. The company is also forecasting a "meaningful decline" in Tryngolza revenue due to necessary price adjustments for broader market access, which is expected to impact financial performance leading up to the launch for the sHTG indication. Furthermore, financial metrics indicate a non-GAAP operating loss forecast of $500 million to $550 million, which is worse than the consensus expectation of a $399 million loss, signifying ongoing financial strain and the likelihood of prolonged losses before achieving profitability.